10X Genomics Inc (TXG)vsVeeva Systems Inc Class A (VEEV)
TXG
10X Genomics Inc
$47.86
+1.81%
HEALTHCARE · Cap: $6.00B
VEEV
Veeva Systems Inc Class A
$211.86
+2.72%
HEALTHCARE · Cap: $33.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Veeva Systems Inc Class A generates 420% more annual revenue ($3.32B vs $638.78M). VEEV leads profitability with a 28.4% profit margin vs -3.5%. VEEV earns a higher WallStSmart Score of 69/100 (B-).
TXG
Avoid20
out of 100
Grade: F
VEEV
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.1%
Fair Value
$60.02
Current Price
$47.86
$12.16 discount
Margin of Safety
+38.9%
Fair Value
$289.59
Current Price
$211.86
$77.73 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Strong operational efficiency at 30.9%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Growing faster than its price suggests
16.3% revenue growth
Areas to Watch
0.0% earnings growth
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Revenue declined 2.6%
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : TXG
The strongest argument for TXG centers on Debt/Equity.
Bull Case : VEEV
The strongest argument for VEEV centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 28.4% and operating margin at 30.9%. Revenue growth of 16.3% demonstrates continued momentum.
Bear Case : TXG
The primary concerns for TXG are EPS Growth, Piotroski F-Score, Return on Equity.
Bear Case : VEEV
The primary concerns for VEEV are P/E Ratio.
Key Dynamics to Monitor
TXG profiles as a turnaround stock while VEEV is a growth play — different risk/reward profiles.
TXG carries more volatility with a beta of 2.04 — expect wider price swings.
VEEV is growing revenue faster at 16.3% — sustainability is the question.
VEEV generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
VEEV scores higher overall (69/100 vs 20/100), backed by strong 28.4% margins and 16.3% revenue growth. TXG offers better value entry with a 68.1% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
10X Genomics Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.
Veeva Systems Inc Class A
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?